Key Takeaways
- ResMed anticipates fiscal year 2027 revenue to reach between $5.75 billion and $5.85 billion.
- $RMD shares climbed 7.2% to $214.40 following the announcement.
- The accelerated $1.85 billion+ in shareholder returns underscores management's confidence in future cash flow.
- Non-GAAP diluted EPS is projected to be between $12.00 and $12.25 for FY27.
- The outlook suggests sustained growth in the sleep apnea and respiratory care markets.
ResMed Targets FY27 Growth, Accelerates Shareholder Returns Amid Market Expansion
ResMed Inc. ($RMD) on Tuesday projected robust fiscal year 2027 financial performance, forecasting revenue between $5.75 billion and $5.85 billion and non-GAAP diluted earnings per share (EPS) of $12.00 to $12.25. Concurrently, the medical device maker announced an acceleration of over $1.85 billion in shareholder returns through dividends and share repurchases, signaling strong confidence in its long-term cash generation capabilities.
The news propelled $RMD shares higher, with the stock surging 7.2% to close at $214.40, marking a significant positive reaction from investors. Trading volume spiked to over 4.5 million shares, more than 250% above its 30-day average, as market participants digested the optimistic multi-year outlook and enhanced capital return strategy.
Market Impact
$RMD's surge added approximately $2.3 billion to its market capitalization, bringing it to roughly $34.3 billion by market close. This marked the stock's largest single-day percentage gain since the third quarter of 2022, when stronger-than-expected earnings fueled a similar rally. The immediate price action pushed $RMD shares above their 50-day moving average for the first time in three weeks, indicating a shift in short-term sentiment.
The positive momentum in $RMD also provided a lift to the broader medical device sector, with the $XLV Health Care Select Sector SPDR Fund gaining 0.8% on the day. Competitors in the respiratory care segment, such as Inspire Medical Systems Inc. ($INSP), saw modest gains of 1.5%, while Philips ($PHG), grappling with past product recalls in its sleep and respiratory care division, also registered a slight uptick of 0.6%, potentially benefiting from renewed investor interest in the overall market.
The accelerated shareholder return program, which includes an unspecified mix of increased dividends and share buybacks over the next several quarters, is likely to enhance $RMD's appeal to income-focused investors and those seeking defensive growth in volatile markets. This move positions ResMed as a company committed to distributing excess capital, a strategy often favored in mature, cash-generative businesses with strong free cash flow. The program represents a substantial commitment, equivalent to over 5% of the company's market capitalization.
What Analysts Are Saying
"ResMed's FY27 guidance far exceeds consensus estimates, reflecting robust underlying demand for sleep apnea devices and a strengthening competitive position," noted Goldman Sachs analysts in a client report. They highlighted the company's ability to navigate supply chain challenges and capitalize on market share gains, projecting a potential re-rating for the stock. The firm reiterated its "Buy" rating with a price target of $235.
Conversely, some analysts expressed caution regarding valuation. "While the long-term outlook is undoubtedly strong, a P/E multiple approaching 30x forward earnings already prices in significant growth," commented a J.P. Morgan strategist, who requested anonymity as they were not authorized to speak publicly. "The key will be execution and how well they fend off renewed competition, especially if Philips re-enters the market more aggressively and without further product quality concerns."
Morgan Stanley analysts, however, focused on the shareholder return aspect. "The accelerated capital return program is a powerful signal of management's confidence in sustained free cash flow generation and provides a floor for the stock amidst broader market volatility," their report stated. They emphasized that the $1.85 billion+ commitment, equivalent to over 5% of the current market cap, demonstrates a disciplined and shareholder-friendly approach to capital allocation.
What to Watch
Investors should closely monitor ResMed's upcoming quarterly earnings reports for consistent progress towards its FY27 targets, specifically looking for sustained revenue growth rates and margin expansion. The next earnings call, expected in late July for the fiscal fourth quarter 2024, will offer initial insights into the trajectory towards these ambitious goals and provide clarity on the precise allocation of the accelerated shareholder returns.
The competitive landscape remains a critical factor. Any significant product launches or market re-entry by key competitors, particularly Philips with its updated DreamStation line, could introduce headwinds for ResMed's market share. Monitoring industry conferences, such as the American Academy of Sleep Medicine (AASM) annual meeting for new technological advancements and competitive strategies, will be crucial for assessing long-term market dynamics.
Key technical levels for $RMD include immediate resistance at $220, a level not consistently breached since early 2023. A sustained move above this could open the path towards the 52-week high of approximately $240, indicating strong bullish momentum. Conversely, strong support is anticipated around the $208 level, corresponding to its 200-day moving average, which could act as a rebound point in case of profit-taking or broader market weakness.
Regulatory developments, including potential changes in Medicare or private insurance reimbursement policies for sleep apnea devices, could also impact demand and pricing power. Investors should track legislative activities related to healthcare spending, medical device approvals, and any shifts in patient access to respiratory care technologies, as these could influence ResMed's ability to meet its long-term financial projections.
